Skip to main content

Advertisement

Log in

Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Lipton RB, Stewart WF, Diamond S, et al.: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646–657.

    Article  PubMed  CAS  Google Scholar 

  2. Menken M, Munsat TL, Toole JF: The global burden of disease study: implications for neurology. Arch Neurol Mar 2000, 57:418–420.

    Article  CAS  Google Scholar 

  3. Goadsby PJ, Lipton RB, Ferrari MD: Migraine: current understanding and treatment. N Engl J Med 2002, 346:257–270.

    Article  PubMed  CAS  Google Scholar 

  4. Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999, 39(suppl 2):S20-S26.

    Article  Google Scholar 

  5. Davies GM, Santanello N, Lipton R: Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000, 20:554–560.

    Article  PubMed  CAS  Google Scholar 

  6. Gallagher RM, Kunkel R: Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003, 43:36–44.

    Article  PubMed  Google Scholar 

  7. Lipton RB, Stewart WF, Simon D: Medical consultation for migraine: results form the American Migraine Study. Headache 1998, 38:87–96.

    Article  PubMed  CAS  Google Scholar 

  8. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ: Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668–1675.

    Article  PubMed  CAS  Google Scholar 

  9. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB: Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002, 22:633–658. Important study.

    Article  PubMed  CAS  Google Scholar 

  10. Silberstein SD: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754–762.

    PubMed  CAS  Google Scholar 

  11. Goadsby PJ: The pharmacology of headache. Prog Neurobiol 2000, 62:509–525.

    Article  PubMed  CAS  Google Scholar 

  12. von Winterfeldt D, Edwards W: Decision Analysis and Behavioral Research. Cambridge: Cambridge University Press; 1987.

    Google Scholar 

  13. Dolan JG: Medical decision-making using the analytic hierarchy process: choice of initial antimicrobial therapy for acute pyelonephritis. Med Decis Making 1989, 9:51–56.

    Article  PubMed  CAS  Google Scholar 

  14. Barriere SL: Formulary evaluation of second-generation cephamycin derivatives using decision analysis. Am J Hosp Pharm 1991, 48:2146–2150.

    PubMed  CAS  Google Scholar 

  15. Schumacher GE: Multiattribute evaluation in formulary decision-making as applied to calcium-channel blockers. Am J Hosp Pharm 1991, 48:301–308.

    PubMed  CAS  Google Scholar 

  16. Eriksen S, Keller LR: A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents. Med Decis Making 1993, 13:118–125.

    Article  PubMed  CAS  Google Scholar 

  17. Dolan JG, Bordley DR: Isoniazid prophylaxis: the importance of individual values. Med Decis Making 1994, 14:1–8.

    Article  PubMed  CAS  Google Scholar 

  18. Brodie MJ, Kwan P: The Star Systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001, 15:1–12.

    Article  PubMed  CAS  Google Scholar 

  19. American Medical Association: Physician Characteristics and Distribution in the US. Chicago: American Medical Association; 2001.

    Google Scholar 

  20. Health Resources and Services Administration: Bureau of Health Professions. State health workforce profiles. http://bhpr.hrsa.gov/healthworkforce/profiles/default.htm. Accessed January 14, 2003.

  21. Saaty TL: How to make a decision: the analytic hierarchy process. Interfaces 1994, 24:19–43.

    Article  Google Scholar 

  22. Dolan JG, Isselhardt BJ Jr, Cappuccio JD: The analytic hierarchy process in medical decision making: a tutorial. Med Decis Making 1989, 9:40–50.

    Article  PubMed  CAS  Google Scholar 

  23. Mooney CZ, Duval RD: Bootstrapping: A Nonparametric Approach to Statistical Interference. Newbury Park, CA: Sage Publications; 1993.

    Google Scholar 

  24. Hwang CL, Yoon KP: Multiattribute Decision-Making: Methods and Applications. Berlin: Springer; 1981.

    Google Scholar 

  25. Yoon KP, Hwang CL: Multiple Attribute Decision-Making: An Introduction. Thousand Oaks, CA: Sage; 1995.

    Google Scholar 

  26. Deng H, Yeh C-H, Willis RJ: Inter-company comparison using modified TOPSIS with objective weights. Comput Oper Res 2000, 27:963–973.

    Article  Google Scholar 

  27. Azar F: Multiattribute decision-making: use of three scoring methods to compare the performance of imaging techniques for breast cancer detection. http://www.seas.upenn.edu/be/Tech_Reports/fredazar_rechreport_MS_BE_00_01.PDF. Accessed October 21, 2002.

  28. Zeleny M: Multiple Criteria Decision Making. New York: McGraw Hill; 1982.

    Google Scholar 

  29. Roon KI, Lipton R, Goadsby PJ, Ferrari M: Placebo in triptan trials: efficacy, tolerability, and consistency. Cephalalgia 2001, 21:405–432.

    Article  Google Scholar 

  30. Baltussen RM, Hutubessy RC, Evans DB, Murray CJ: Uncertainty in cost-effectiveness analyses: probabilistic uncertainty analysis and stochastic league tables. In GPE Discussion Paper Series: No 34. Geneva World Health Organization. www nt.who.int/whosis/statistics/discussion_papers/pdf/paper34pdf. Accessed November 2003.

  31. Brodie MJ: Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia 1999, 40(suppl 6): S17-S22; discussion, S73–S74.

    Article  PubMed  CAS  Google Scholar 

  32. Crawford PM, Pope S. The Star Systems. CNS Drugs 2001, 15:13–15.

    Article  CAS  Google Scholar 

  33. Cutrer FM, Goadsby PJ, Ferrari M, et al.: Prioritization of treatment attributes in selecting an oral triptan: a survey of U.S. primary care physicians. Headache 2002, 42:392–393.

    Google Scholar 

  34. Lipton RB, Liberman J, Goadsby PJ, et al.: An assessment of the priorities of US migraineurs with respect to prespecified triptan treatment attributes. Headache 2002, 42:394–395.

    Google Scholar 

  35. Dodick DW, Lipton RB, Goadsby PJ, et al.: Prioritizing triptan treatment attributes: a pilot study. Neurology 2002, 58(suppl 3):A129.

    Google Scholar 

  36. McCrory D: Selecting the preferred triptans. Cephalalgia 2002, 22:575–576. Noteworthy study.

    Google Scholar 

  37. Lipton RB, Bigal ME, Rush SR, et al.: Migraine practice patterns among neurologists. Neurology 2004, 62:1926–1931.

    PubMed  CAS  Google Scholar 

  38. Moss L, Goldstein H: The Recall Method in Social Surveys. London: University of London Institute of Education; 1979.

    Google Scholar 

  39. Abi-Zeid I, Belanger M, Guitouni A, et al.: A Multicriteria Method for Evaluating Courses of Action in Canadian Airspace Violation Situations. http://www.dodccrp.org/Proceedings/DOCS/wcd00000/wcd00091.htm, 2002. Accessed November 2003.

  40. Trowbridge R, Weingarten S: Clinical decision support systems. Chapter 53 in Evidence Report/Technology Assessment no 43, Making Health Care Safer: a Critical Analysis of Patient Safety Practices. Agency for Healthcare Research and Quality, Washington. http://www.ahcpr.gov/clinic/ptsafety/chap53.htm, 2001. Accessed November 2003.

    Google Scholar 

  41. Purdy RA: Evidence-based migraine therapy: learning needs and knowledge assessment. Cephalalgia 2000, 20(suppl 2):5–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodick, D.W., Lipton, R.B., Ferrari, M.D. et al. Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. Current Science Inc 8, 435–442 (2004). https://doi.org/10.1007/s11916-004-0064-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-004-0064-2

Keywords

Navigation